Cargando…
Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells
Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripher...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103844/ https://www.ncbi.nlm.nih.gov/pubmed/25036145 http://dx.doi.org/10.1371/journal.pone.0102197 |
_version_ | 1782327203972775936 |
---|---|
author | Zhang, Peng Yi, Shuhong Li, Xi Liu, Ruilei Jiang, Hua Huang, Zenan Liu, Yu Wu, Juekun Huang, Yong |
author_facet | Zhang, Peng Yi, Shuhong Li, Xi Liu, Ruilei Jiang, Hua Huang, Zenan Liu, Yu Wu, Juekun Huang, Yong |
author_sort | Zhang, Peng |
collection | PubMed |
description | Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripheral blood monocytes, and explored the biological characteristics of fusion vaccine and its anti-tumor effects in vitro. Day-3 mature DCs were generated from day-2 immature DCs by adding cocktails composed of TNF-α, IL-1β, IL-6 and PEG(2). Day-3 mature DCs were identified and electofused with breast cancer cells to generate fusion vaccine. Phenotype of fusion cells were identified by fluorescence microscope and flow cytometer. The fusion vaccine was evaluated for T cell proliferation, secretion of IL-12 and IFN-γ, and induction of tumor-specific CTL response. Despite differences in morphology, day-3 and day-7 DC expressed similar surface markers. The secretion of IL-12 and IFN-γ in fusion vaccine group was much higher than that in the control group. Compared with control group, DC-tumor fusion vaccine could better stimulate the proliferation of allogeneic T lymphocytes and kill more breast cancer cells (MDA-MB-231) in vitro. Day-3 DCs had the same function as the day-7 DCs, but with a shorter culture period. Our findings suggested that day-3 DCs fused with whole apoptotic breast cancer cells could elicit effective specific antitumor T cell responses in vitro and may be developed into a prospective candidate for adoptivet immunotherapy. |
format | Online Article Text |
id | pubmed-4103844 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-41038442014-07-21 Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells Zhang, Peng Yi, Shuhong Li, Xi Liu, Ruilei Jiang, Hua Huang, Zenan Liu, Yu Wu, Juekun Huang, Yong PLoS One Research Article Dendritic cells (DCs) are professional antigen-presenting cells (APCs) in human immune system. DC-based tumor vaccine has met with some success in specific malignancies, inclusive of breast cancer. In this study, we electrofused MDA-MB-231 breast cancer cell line with day-3 DCs derived from peripheral blood monocytes, and explored the biological characteristics of fusion vaccine and its anti-tumor effects in vitro. Day-3 mature DCs were generated from day-2 immature DCs by adding cocktails composed of TNF-α, IL-1β, IL-6 and PEG(2). Day-3 mature DCs were identified and electofused with breast cancer cells to generate fusion vaccine. Phenotype of fusion cells were identified by fluorescence microscope and flow cytometer. The fusion vaccine was evaluated for T cell proliferation, secretion of IL-12 and IFN-γ, and induction of tumor-specific CTL response. Despite differences in morphology, day-3 and day-7 DC expressed similar surface markers. The secretion of IL-12 and IFN-γ in fusion vaccine group was much higher than that in the control group. Compared with control group, DC-tumor fusion vaccine could better stimulate the proliferation of allogeneic T lymphocytes and kill more breast cancer cells (MDA-MB-231) in vitro. Day-3 DCs had the same function as the day-7 DCs, but with a shorter culture period. Our findings suggested that day-3 DCs fused with whole apoptotic breast cancer cells could elicit effective specific antitumor T cell responses in vitro and may be developed into a prospective candidate for adoptivet immunotherapy. Public Library of Science 2014-07-18 /pmc/articles/PMC4103844/ /pubmed/25036145 http://dx.doi.org/10.1371/journal.pone.0102197 Text en © 2014 Zhang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zhang, Peng Yi, Shuhong Li, Xi Liu, Ruilei Jiang, Hua Huang, Zenan Liu, Yu Wu, Juekun Huang, Yong Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells |
title | Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells |
title_full | Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells |
title_fullStr | Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells |
title_full_unstemmed | Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells |
title_short | Preparation of Triple-Negative Breast Cancer Vaccine through Electrofusion with Day-3 Dendritic Cells |
title_sort | preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103844/ https://www.ncbi.nlm.nih.gov/pubmed/25036145 http://dx.doi.org/10.1371/journal.pone.0102197 |
work_keys_str_mv | AT zhangpeng preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells AT yishuhong preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells AT lixi preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells AT liuruilei preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells AT jianghua preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells AT huangzenan preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells AT liuyu preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells AT wujuekun preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells AT huangyong preparationoftriplenegativebreastcancervaccinethroughelectrofusionwithday3dendriticcells |